United Therapeutics Corporation

The transcript from the Q1 2026 United Therapeutics earnings call does not mention any current or planned fundraising activities through debt or equity. Key points: - No references to new debt issuance or equity offerings during the call. - Discussion focused primarily on product development, regulatory pathways, commercial strategies, and clinical trial progress. - Financial remarks addressed revenue performance, product demand, and future growth expectations. - No commentary on capital raising or financing activities, suggesting no immediate plans for fundraising via debt or equity at this time. In summary, United Therapeutics did not disclose any current or prospective debt or equity fundraising initiatives in this call.

- United Therapeutics is investing in expanding manufacturing capacity to support the growing demand for Tyvaso DPI and ralinepag. - They will utilize the Danbury, Connecticut MannKind production plant and the new United Therapeutics North Carolina DPI facility. - Sales force investments are planned to be deployed mid-2026 to expand reach and capture more of the addressable PH-ILD and PAH markets. - Continued development and commercial scale-up of multiple product formulations (DPI, SMI, nebulized) for various indications including IPF and PAH. - Ongoing regulatory and clinical development investments to support new product filings and launches, like ralinepag oral and inhaled formulations. - Leveraging MannKind’s crystal carrier IP for ralinepag solid dose and DPI formulations, indicating strategic collaboration investment.

- United Therapeutics projects a $4 billion revenue run rate by the end of 2027, more than doubling current revenues. - Ralinepag and the IPF indication alone are expected to drive this growth. - The launch of oral ralinepag is anticipated by mid-next year, assuming smooth FDA approval. - Tyvaso DPI has shown 9% year-over-year growth, driven by increased patient demand. - New formulations like Tyvaso DPI, Tyvaso SMI, and ralinepag DPI are expected to expand market reach in PH-ILD, PAH, IPF, and PPF. - The company plans to invest in commercial sales force expansion mid-year to focus on capturing uncaptured markets. - Patient shipments and prescriber engagement have steadily increased in recent months. - The organization aims for sustained double-digit long-term growth fueled by innovation and expanded product offerings.

- United Therapeutics aims to reach a $4 billion revenue run rate by the end of 2027, more than doubling current revenues. - The launch of ralinepag and multiple formulations of Tyvaso (nebulized, DPI, and SMI) is expected to drive significant growth. - Ralinepag, as a once-daily oral prostacyclin, is anticipated to become the most prescribed prostacyclin for PAH, contributing strongly to revenue. - The IPF indication, with Tyvaso and its DPI and SMI forms, is also projected as a major revenue driver, with expectations to become the most prescribed therapy for IPF. - The company plans to expand commercial efforts mid-2026 to capture more of the PH-ILD and PAH markets. - Double-digit long-term growth in earnings and profits is anticipated, supported by a durable, high-performing commercial engine and ongoing product innovation.

- The company expects a strong demand trajectory, aiming for a $4 billion revenue run rate by the end of 2027, more than doubling current revenues driven by ralinepag and IPF indications. - There is significant patient demand for Tyvaso DPI, with patient shipments growing for the last 5 months and increased patient graduation to higher doses. - The launch of ralinepag oral formulation is expected mid-next year following anticipated FDA approval, targeting a multibillion-dollar market opportunity. - Preparations for product launches, including IPF indications and ralinepag formulations, are underway with expanded sales force investments planned for mid-2026. - The company anticipates tens of thousands of treated patients across PAH, ILD, IPF, and PPF indications, utilizing full capacity of manufacturing facilities. - They expect to complete Phase I studies for new formulations (e.g., ralinepag DPI) by end of the year and rapidly proceed to efficacy studies, positioning their orderbook favorably.